



## EMMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001

Tel: 022-35661373 / 35664530 Email: [enquiries@ebnl.org](mailto:enquiries@ebnl.org) Website: [www.ebnl.org](http://www.ebnl.org)

Investors Grievance Email: [investors@ebnl.org](mailto:investors@ebnl.org) CIN No. L24110MH1992PLC065942

**Date: August 07, 2025**

To,  
The Manager  
Listing Department,  
Bombay Stock Exchange Limited,  
P. J. Tower, Dalal Street,  
Mumbai – 400 001

**Ref: --Security Code No.524768**

**Sub: Outcome of Board Meeting**

The Board of Directors at their meeting held today i.e. August 07, 2025 has transacted the following items of business:

**1. Unaudited Financial Results for the Quarter ended June 30, 2025:**

Pursuant to Regulation 33(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are forwarding herewith a copy of Unaudited Financial Results for the Quarter ended 30.06.2025.

The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 07.08.2025 (i.e today).

We also enclose "Limited Review Report" dated 07.08.2025, issued by Statutory Auditors, M/s. V. Nagarajan & Co., Chartered Accountant(s), FRN No.: 004879N, in respect of Unaudited Financial Results for the Quarter ended 30.06.2025. The results are attached at "Annexure A".

**2. Annual General Meeting:**

The 33<sup>rd</sup> Annual General Meeting of the Company is scheduled to be held on Friday September 26, 2025 at 10:30 a.m. through video conferencing pursuant to General Circular Nos. 14/2020, 17/2020, 20/2020, 02/2021, 21/2021, 02/2022, 10/2022, 09/2023 and 09/2024 dated April 8, 2020, April 13, 2020, May 5, 2020, January 13, 2021, December 14, 2021, May 5, 2022, December 28, 2022, September 25, 2023 and September 19, 2024 respectively ("MCA Circulars") (hereinafter collectively referred to as "MCA Circulars") and Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020, Circular No. SEBI/HO/CFD/CMD2/CIR/P/2022/62 dated May 13, 2022, Circular No. SEBI/HO/CFD/PoD-2/P/CIR/2023/4 dated January 5, 2023, Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2023/167 dated October 7, 2023 and Circular No. SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 3, 2024 ("SEBI circulars"). In compliance with these MCA and SEBI Circulars, there has been certain relaxations from compliance with certain provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), issued in this behalf.

In compliance with these MCA and SEBI Circulars, provisions of the Companies Act, 2013 (the "Act") and the Listing Regulations, the ensuing 33<sup>rd</sup> AGM of the Company will be conducted through VC/ OAVM facility, which does not require physical



## EMIMESSAR BIOTECH & NUTRITION LIMITED

29, Kamer Building, 4th floor, 38, Cawasji Patel Street, Fort, Mumbai – 400 001

Tel: 022-35661373 / 35664530 Email: [enquiries@ebnl.org](mailto:enquiries@ebnl.org) Website: [www.ebni.org](http://www.ebni.org)

Investors Grievance Email: [investors@ebni.org](mailto:investors@ebni.org) CIN No. L24110MH1992PLC065942

presence of members at a common venue. The deemed venue for the 33<sup>rd</sup> AGM shall be the Registered Office of the Company.

### 3. E voting and Cut-off date:

In compliance with the provisions of Section 108 of the Companies Act, 2013, read with Rule 20 Companies (Management and Administration) Rules as amended up to date and Regulation 44 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, the Company has decided to provide the facility to members to exercise their right to vote at the Annual General Meeting (AGM) by electronic means and the business may be transacted through e-Voting services provided by MUFG Intime India Private Limited formerly known as Link Intime India Pvt. Ltd (MUFG).

The cutoff date for the limited purpose of remote e-voting is September 19, 2025.

The remote e-voting period will commence on Tuesday, September 23, 2025 at 09:00 A.M. IST and end on Thursday, September 25, 2025 at 5:00 P.M. IST. During this period shareholders of the Company, holding shares either in physical form or in dematerialised form, as on cut-off date i.e. Friday, September 19, 2025, may cast their vote electronically.

The Meeting commenced at 12:00 noon and concluded at 02:00 p.m.

Kindly take the above on record.

For **EMIMESSAR BIOTECH & NUTRITION LIMITED**

**Srinivasa Raghavan Mathurakavi Ayyangar**  
(Managing Director)

Encl: As above



Limited Review Report on Unaudited Financial Results of Emmessar Biotech & Nutrition Limited for the Quarter ended 30<sup>th</sup> June 2025 pursuant to Regulation 33 of Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Emmessar Biotech & Nutrition Limited

1. We have reviewed the accompanying Statement of unaudited financial results of **Emmessar Biotech & Nutrition Limited** ("the Company") for the quarter ended 30<sup>th</sup> June 2025, ("The Statement").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of Securities and Exchange Board of India(Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review in accordance with the Standards on Review Engagements (SRE) 2410, 'Review on Interim Financial Information Performed by the Independent auditor of the Entity' issued by the Institute of Chartered Accountants of India. These standards require that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to enquiries of the Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



For V Nagarajan & Co.  
Chartered Accountants  
ICAI Firm Regn. No. 004879N



Shankar Cherekupally  
Partner  
Membership No. 252304  
UDIN: 25252304BMHXCN5244

Place: Hyderabad  
Date: 07<sup>th</sup> August, 2025

**UNAUDITED FINANCIAL RESULTS (STANDALONE) FOR THE QUARTER ENDED 30TH JUNE 2025**

		(Rupees in Lakhs)			
Sr. No	Particulars	Quarter Ended		Year Ended	
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		Unaudited	Audited	Unaudited	Audited
	<b>PART A</b>				
1	Revenue from Operations	9.28	9.58	7.92	61.09
2	Other Income	53.42	60.78	45.73	200.87
	<b>Total Income (1 + 2)</b>	<b>62.70</b>	<b>70.36</b>	<b>53.65</b>	<b>261.96</b>
	<b>PART B</b>				
3	<b>Expenses</b>				
	(a) Cost of material consumed	1.16	4.30	1.04	6.90
	(b) Purchase of Stock-trade	0.00	-	0.00	12.64
	(c) Change in Inventories of Finished goods	1.94	(1.06)	1.23	(1.36)
	(d) Employee Benefit Expenses	24.50	21.41	23.29	92.90
	(e) Depreciation & Amortisation of Assets	2.49	2.44	2.44	9.76
	(f) Finance cost	0.06	0.06	0.00	0.06
	(g) Other Expenditure	9.42	17.32	9.83	45.24
	<b>Total Expenses (a to g)</b>	<b>39.57</b>	<b>44.47</b>	<b>37.82</b>	<b>166.14</b>
4	Profit / (loss) from Operations before exceptional items & Tax (A-B)	23.13	25.89	15.84	95.82
5	Exceptional items	0.00	0.00	0.00	0.00
6	Profit / (loss) before tax (4 - 5)	<b>23.13</b>	<b>25.89</b>	<b>15.84</b>	<b>95.82</b>
7	<b>Tax Expenses</b>				
	1. Current Tax	(6.00)	(11.30)	-3.00	(27.30)
	2. Deferred Tax	(0.01)	0.76	-3.94	(20.17)
	3. Excess/short provision of earlier years	0.00	(22.21)	0.00	(16.74)
	<b>Total Tax Expense (1+2+3)</b>	<b>(6.01)</b>	<b>(32.75)</b>	<b>(6.94)</b>	<b>(64.21)</b>
8	Net Profit / (loss) after tax (6 - 7)	17.12	(6.86)	8.90	31.61
9	Less: Other Comprehensive Income	0.00	1.06	0.00	1.06
10	Total comprehensive income for the period and Other Comprehensive Income	<b>17.12</b>	<b>(7.92)</b>	<b>8.90</b>	<b>30.55</b>
11	<b>Paid-up Equity Share Capital</b>	<b>499.61</b>	<b>499.61</b>	<b>499.61</b>	<b>499.61</b>
	(Face Value of the share)	10.00	10.00	10.00	10.00
	Other Equity	-	-	-	271.19
12	<b>Earning per Shares</b>				
	a) Basic	0.34	(0.16)	0.18	0.61
	b) Diluted	0.34	(0.16)	0.18	0.61

**Notes:**

- The above results were taken on record by the Board of Directors and the Audit Committee at their meeting held on 7th August 2025 and have been subjected to Limited Review by the Statutory Auditors. The review report of the Statutory Auditors is being filed with the BSE.
- The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS-34) as prescribed under Section 133 of Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rule 2015 and the Companies (Indian Accounting Standards) Amendments Rule 2016 as amended thereafter.
- The Company operates two segments i.e. Healthcare and rent on leasehold land during this quarter.
- No Investor Compliant was received for the quarter ended 30th June 2025
- Previous years' figures have been regrouped wherever considered necessary.

for Emmessar Biotech & Nutrition Ltd

*[Signature]*

Srinivasa Raghavan Mathurakavi Ayyangar  
Chairman & Managing Director  
DIN: 00090266

Mumbai  
07-Aug-25





**EMMESSAR BIOTECH & NUTRITION LIMITED**

Regd Office: T-3/2, MIDC, Talaja, Raigad District, Maharashtra State

CIN: L24110MH1992PLC065942

Segmentwise Revenue, Results and Capital Employed for the Quarter Ended 30th June 2025


[Rs. In Lakhs]

		Quarter Ended			Year Ended
		30.06.2025	31.03.2025	30.06.2024	31.03.2025
		Unaudited	Audited	Unaudited	Audited
1	1. Segment Revenue				
a	Healthcare	9.28	9.57	7.92	61.09
b	Rent on Leasehold Land	41.33	40.88	37.16	152.36
c	Others	12.09	19.91	8.57	48.51
	Total:	62.70	70.36	53.65	261.96
	Less: Inter Segment Revenue	-	-	-	-
	Net Sales / Income from Operations	62.70	70.36	53.65	261.96
2	Segment Results (Profit / Loss) tax				
a	Healthcare	6.18	6.33	5.15	39.12
b	Rent on Leasehold Land	41.10	40.65	36.93	151.44
c	Others	12.09	19.91	8.57	48.51
	Total:	59.37	66.89	50.65	239.07
	Less:				
	Interest	-	-	-	-
	Other Unallocable Expenditure (Net off)	36.24	41.00	34.81	143.25
	Total Profit before Tax & Exceptional items	23.13	25.89	15.84	95.82
3	Capital Employed (Segment Assets - Segment Liabilities)				
a	Healthcare	11.89	13.83	12.01	13.83
b	Leasehold Land	(2.82)	(2.59)	(1.89)	(2.59)
c	Others	804.40	767.03	728.34	767.03
	Total:	813.46	778.27	738.46	778.27

Note: The Fixed Assets are employed for the general enterprise and are not segmental in nature.

The above results were taken on record at a meeting of the Board of Directors held on 7th August 2025

Mumbai  
07-Aug-25

  
 By order of the Board  
 Srinivasa Raghavan Mathurakavi Ayyangar  
 Chairman & Managing Director  
 DIN: 00090265

